US Patent 7910567 Opticin nucleic acid administration reduces blood vessel formation

Patent 7910567 was granted and assigned to The University of Manchester on March, 2011 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

The University of Manchester

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7910567

Date of Patent

March 22, 2011

Patent Application Number

12101717

Date Filed

April 11, 2008

Patent Primary Examiner

‌

Thaian N. Ton

Patent abstract

The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of conditions characterized by excessive activity and/or migration of monocytes and/or macrophages. Suitable agents may include class III SLRPs such as opticin. Methods of treatment using agents able to promote class III SLRP activity are also provided.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7910567 Opticin nucleic acid administration reduces blood vessel formation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API